Promethera Biosciences Elects Charles L. Dimmler, III as Chairman of Board
10 April 2018 - - Mont-Saint-Guibert, Belgium-based cell-based medicines company Promethera Biosciences SA, has appointed Mr Charles L. Dimmler, III as the new chairman of the board, effective immediately, the company said.
He replaces Prof Dr Christof Hettich, who will keep a seat as director.
Dimmler is a highly experienced international life sciences entrepreneur, venture capitalist and business operating executive, currently being vice chairman of Torreya Partners, LLC, a boutique investment banking firm specialized exclusively in the business of life sciences and based in New York, USA.
His long experience as a chairman, CEO, and COO encompasses companies including Ceramedix Holding, LLC, Ore Pharmaceuticals, Nobex Corp., and Applied Immune Sciences. Dimmier also served as chairman and CEO of Lundbeck, Inc.; as well as chief investment officer of H. Lundbeck A/S.
In addition to his entrepreneurial career, he was a general partner at Hambro International Equity Partners and Cross Atlantic Partners, two US venture capital units of the London-based merchant banking firm, Hambros plc.
Dimmler received an undergraduate degree at the University of California at Davis and engaged in post graduate education at Harvard Business School, Columbia University School of Business and The Wharton School. He is a former infantry officer in the United States Marine Corps.
Promethera is a global innovator in severe liver diseases and liver cell-based medicines therapeutics specialist whose mission is to help enable patients to overcome acute and chronic liver diseases.
The company's lead clinical program, derived from its patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. Promethera operates out of Rand D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.